Genetically-encoded discovery and development of peptide-macrocycle imaging agents for PD-L1
- 1University of Alberta
Abstract
The unique cell surface composition of tumor cells forms the molecular basis for many targeting and cell-based therapies. Here, we describe the development of novel peptide-based targeting agents for programmed death ligand 1 (PD-L1). Molecular imaging by peptide agents, coupled with therapeutic intervention using the same modality, represents a critical advancement in cancer management. Whole-body PET imaging of PD-L1 expression offers a superior alternative to traditional immuno-histochemistry, making PD-L1 radiodiagnostic imaging a highly sought-after modality. PD-L1 targeting modalities developed for clinical imaging to date can be divided into antibodies, protein domains, and small macrocyclic peptides with fewer than 20 amino acids. The latter modalities can address many challenges seen in antibody-based targeting vectors. All potent PD-L1 targeting peptide modalities reported to date rely extensively on non-canonical amino acids (ncAAs). Here, we report a comprehensive structure-activity relationship (SAR) analysis of a family of macrocycles discovered from an Sx2Cx8Cx2 phage-display library composed entirely of natural amino acids (x represents 19 natural amino acids excluding Cys). Using >10,000 variants in ''focused'' phage-display libraries, we optimized these macrocycles to achieve single-digit-nanomolar potency in protein- and cell-based assays. En route to this optimization, the activity of 216 synthetic macrocycles towards PD-L1 was measured in five distinct assays; two leads have been evaluated by imaging in tumor xenografts in mice, and the X-ray structure of one advanced lead in complex with PD-L1 has been determined at 2.78 [A] resolution. This publication demonstrates the development potential of PD-L1-targeting macrocycles that do not require extensive incorporation of ncAAs and the democratization of discovery by mapping the optimization path to single-digit-nanomolar assets for targeted radiopharmaceuticals via canonical phage-display technology.
Related
- DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer's Disease Patient-Derived Neurons
- Calpain and caspase regulate Aβ peptide production via cleavage of KINDLIN2 encoded by the AD-associated gene FERMT2
- De novo macrocyclic peptide discovery produces potent class A GPCR ligands with diverse pharmacology
- Development and design rules for a modular human peptide-tag adaptor CAR T cell system
- 891 Pre-clinical development of a best-in-class bispecific T cell engager targeting a highly abundant peptide for the treatment of melanoma
BibTeX
@misc{derda2026geneticallyencoded,
title = {{Genetically-encoded discovery and development of peptide-macrocycle imaging agents for PD-L1}},
author = {R. Derda and V. Albert and M. L. Michnik and G. Bao and T. K. Bahadur and W. Kirby and H. Irwin and K. Maiorana and J. Walker and G. Sharma and R. Mistry and A. Zakaria and D. Yazdan and J. Wang and M. Truksa and Y. Cai and J. Woodfield and M. Kaur and Z. O'Gara and A. Dorian and M. Wuest and C. Bergman and J. S. Klassen and H. W. Kim and T. K. Sawyer and T. McMullen and F. Wuest},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.11.750985},
url = {https://www.biorxiv.org/content/10.64898/2026.09.11.750985v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Genetically-encoded discovery and development of peptide-macrocycle imaging agents for PD-L1
AU - R. Derda
AU - V. Albert
AU - M. L. Michnik
AU - G. Bao
AU - T. K. Bahadur
AU - W. Kirby
AU - H. Irwin
AU - K. Maiorana
AU - J. Walker
AU - G. Sharma
AU - R. Mistry
AU - A. Zakaria
AU - D. Yazdan
AU - J. Wang
AU - M. Truksa
AU - Y. Cai
AU - J. Woodfield
AU - M. Kaur
AU - Z. O'Gara
AU - A. Dorian
AU - M. Wuest
AU - C. Bergman
AU - J. S. Klassen
AU - H. W. Kim
AU - T. K. Sawyer
AU - T. McMullen
AU - F. Wuest
PY - 2026
DA - 2026/09/11
PB - bioRxiv
DO - 10.64898/2026.09.11.750985
UR - https://www.biorxiv.org/content/10.64898/2026.09.11.750985v1
AB - The unique cell surface composition of tumor cells forms the molecular basis for many targeting and cell-based therapies. Here, we describe the development of novel peptide-based targeting agents for programmed death ligand 1 (PD-L1). Molecular imaging by peptide agents, coupled with therapeutic intervention using the same modality, represents a critical advancement in cancer management. Whole-body PET imaging of PD-L1 expression offers a superior alternative to traditional immuno-histochemistry, making PD-L1 radiodiagnostic imaging a highly sought-after modality. PD-L1 targeting modalities developed for clinical imaging to date can be divided into antibodies, protein domains, and small macrocyclic peptides with fewer than 20 amino acids. The latter modalities can address many challenges seen in antibody-based targeting vectors. All potent PD-L1 targeting peptide modalities reported to date rely extensively on non-canonical amino acids (ncAAs). Here, we report a comprehensive structure-activity relationship (SAR) analysis of a family of macrocycles discovered from an Sx2Cx8Cx2 phage-display library composed entirely of natural amino acids (x represents 19 natural amino acids excluding Cys). Using >10,000 variants in ''focused'' phage-display libraries, we optimized these macrocycles to achieve single-digit-nanomolar potency in protein- and cell-based assays. En route to this optimization, the activity of 216 synthetic macrocycles towards PD-L1 was measured in five distinct assays; two leads have been evaluated by imaging in tumor xenografts in mice, and the X-ray structure of one advanced lead in complex with PD-L1 has been determined at 2.78 [A] resolution. This publication demonstrates the development potential of PD-L1-targeting macrocycles that do not require extensive incorporation of ncAAs and the democratization of discovery by mapping the optimization path to single-digit-nanomolar assets for targeted radiopharmaceuticals via canonical phage-display technology.
ER -